A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex

This study has been completed.
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002163
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: November 1998

November 2, 1999
June 23, 2005
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00002163 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex
A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex

To evaluate the benefit of adding 1592U89 to current antiretroviral therapies for AIDS dementia complex and to assess the safety and tolerance of the treatment regimens.

Patients must be on stable antiretroviral treatment for at least 6 weeks prior to study entry and will then be stratified depending on whether their regimen contains zidovudine (ZDV). Each stratum will be randomized separately to receive 1592U89 or placebo for 12 weeks. For the subsequent 40 weeks, open-label 1592U89 will be offered.

Interventional
Phase 3
Endpoint Classification: Safety Study
Masking: Double-Blind
Primary Purpose: Treatment
  • AIDS Dementia Complex
  • HIV Infections
Drug: Abacavir sulfate
Not Provided
Lanier ER, Sturge G, McClernon D, Brown S, Halman M, Sacktor N, McArthur J, Atkinson JH, Clifford D, Price RW, Simpson D, Torres G, Catalan J, Marder K, Power C, Hall C, Romero C, Brew B. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. AIDS. 2001 Apr 13;15(6):747-51.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria

Patients must have:

  • Documented HIV infection.
  • Evidence of HIV - associated dementia.
  • Been on stable antiretroviral treatment for a minimum of 6 weeks prior to study entry.

Exclusion Criteria

Co-existing Condition:

Patients with any of the following symptoms or conditions are excluded:

  • Debilitated as a result of their HIV disease, associated illness or therapies who the investigator determines will not be able to complete the 12 week randomized dosing period.
  • Memorial Sloan-Kettering (MSK) score of >= 3 for dementia.
  • Confounding neurological diseases which may interfere with interpretation of neurological and neurophysical assessments.
  • Malabsorption syndrome or other gastrointestinal dysfunction which renders them unable to take oral medication.
  • Chronic diseases such as diabetes, congestive heart failure, cardiomyopathy, other cardiac dysfunctions, etc., which in the investigator's opinion would compromise the safety of the patient.
  • Symptomatic AIDS-defining opportunistic infection not responsive to therapy.

Concurrent Medication:

Excluded:

  • Treatment with cytotoxic chemotherapeutic agents within the first 12 weeks of the study.
  • Treatment with nerve growth factor within the first 12 weeks of study.
  • The use of narcotic analgesics, sedatives, benzodiazepines, antidepressants, anti-psychotic agents and other psychoactive drugs which would interfere with the assessment of the neurological and neurophysical status of the patient.
  • Use of stavudine (d4T) during the first 12 weeks of the study.
  • Immunomodulating agents (except GM/G-CSF or epoietin).
  • Psychoactive drugs (at the investigator's discretion).

Concurrent Treatment:

Excluded:

  • Treatment with radiation therapy within the first 12 weeks of the study.

NOTE:

  • With the exception of local treatment for Kaposi's sarcoma.

Patients with any of the following prior conditions are excluded:

  • Previous neurological disease unrelated to HIV infection.
  • History of clinically apparent hepatitis within the last 6 months.
  • History of clinically apparent pancreatitis in the last 6 months.

Prior Medication:

Excluded:

  • Treatment with cytotoxic chemotherapeutic agents within 1 month of entry.
  • Participation in investigational antiretroviral trials within the past 3 months.
  • HIV vaccine within the past 3 months.
  • Treatment with immunomodulating agents such as systemic corticosteroids, interleukins, thalidomide, anticytokine agents, anti-oxidants or interferons within 1 month of study entry.
  • Nerve growth factor.

Prior Treatment:

Excluded:

  • Treatment with radiation therapy within 1 month of entry.

NOTE:

  • With the exception of local treatment for Kaposi's sarcoma.

Risk Behavior:

Excluded:

Current alcohol or illicit drug use which may interfere with the patient's ability to comply with the study protocol.

Required:

  • Stable antiretroviral treatment that has been ongoing for a minimum of 6 weeks prior to study entry, may or may not include ZDV.

Required:

  • Stable antiretroviral treatment for a minimum of 6 weeks prior to study entry.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00002163
238B, CNAB 3001
Not Provided
Not Provided
Glaxo Wellcome
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
November 1998

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP